Answers are grounded in this paper and cite their sources.
The metabolism of salicylazosulfapyridine in steady state was studied in 26 healthy volunteers, in 19 colitis patients (17 of whom had ulcerative colitis and 2 Crohn's disease), and in 10 subjects in whom the colon had been removed (ileostomized subjects). This study provides evidence that the site of reductive cleavage of the azo linkage of salicylazosulfapyridine in man is the colon. Subjects with an intact colon excreted 60.5% ± 4.3% of the dose in the urine as sulfapyridine metabolites (which are formed after azo link cleavage), while ileostomized sub;ects excreted 7.1% ± 6.8% of the dose of sulfapyridine metabolites. The metabolic pattern of sulfapyridine in healthy volunteers was in the main similar to that in colitis patients. The serum concentrations of the various metabolites were measured in colitis patients and in ileostomized subjects. The levels of salicylazosulfapyridine on a dose of 2 gm daily were similar in the two groups with a median of about 5 µg per milliliter. The serum concentration of total sulfapyridine ranged from 17 to 40 µg per milliliter in colitis patients and from 0 to 8 µg per milliliter in ileostomized subjects. Phenobarbital sodium, 50 mg nightly, was taken for 5 to 7 nights. In subjects with an intact colon phenobarbital depressed the urinary excretion of salicylazosulfapyridine by 18%, either by induction of a hepatic azo reductase or by enhancement of the biliary excretion of the drug. The proportions in urine of O‐glucuronidized sulfapyridine were increased by 10%, at the cost of acetylation of sulfapyridine. Phenobarbital had no detectable effects on the metabolic pattern of salicylazosulfapyridine in ileostomized subjects.
No takes yet. Share an insight, caveat, or question.
Schröder et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: